513.68MMarket Cap-4994P/E (TTM)
9.540High8.680Low228.86KVolume9.540Open8.940Pre Close2.09MTurnover0.88%Turnover RatioLossP/E (Static)55.59MShares10.25052wk High-18.15P/B241.60MFloat Cap2.70052wk Low--Dividend TTM26.15MShs Float28.265Historical High--Div YieldTTM9.62%Amplitude2.700Historical Low9.141Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet